Potentially disruptive technologies

We have three highly differentiated technologies focused on next generation anthracycline, immune/transcription modulators and metabolism/glycosylation inhibitors.


Attacking the most difficult cancers & viruses

We are developing treatments for highly resistant viruses and cancers such as acute myeloid leukemia; cutaneous T-cell lymphoma, a deadly form of skin cancer; pancreatic cancer, glioblastoma, brain tumors; and COVID-19.

Partnerships & Collaborations

Relationships with world-class cancer centers

Critical to our efforts is leveraging our continued collaborations and partnerships with leading cancer centers like MD Anderson Cancer Center, Emory University, the Mayo Clinic and others.

Priority Development Pipeline

MBRX Priority Development Pipeline

Follow-on Development Pipeline

MBRX Follow On Pipeline


The Next Generation Anthracycline

Annamycin is a unique next-generation liposome formulated anthracycline that has been designed to eliminate cardiotoxicity and avoid the multidrug resistance mechanisms that often defeat currently approved anthracyclines.


An Immune/Transcription Modulator

WP1066 is one of several Immune/Transcription Modulators, designed to stimulate the immune response to tumors by inhibiting the errant activity of Regulatory T-Cells while also inhibiting key oncogenic transcription factors, including p-STAT3, c-Myc and HIF-1α.


A Metabolism/Glycosylation Inhibitor

WP1122 is a prodrug of a well-known glucose decoy called 2-deoxy-D-glucose, or 2-DG, which enables increased cellular uptake, increased drug half-life and, importantly, an increased ability to cross the blood brain barrier, enabling greater uptake in the brain.